According to the report, the Asia Pacific Digital Breast Tomosynthesis (DBT) Equipment Market size is valued at USD 268.55 million in 2022 and is expected to grow at a CAGR of 14.8% to reach USD 535.47 million by 2027 from 2022 to 2027.
The increasing prevalence of breast cancer will lead to the market's growth during the projected period. According to Breastcancer.org, during 2019, 268,650 new cases of invasive breast cancer are expected to be diagnosed in women, along with 62,950 new cases of non-invasive breast cancer. In addition, the increase in government initiatives to promote awareness of breast cancer treatment and the growing female population are other key factors responsible for the growth of the market in the APAC region.
According to the World Health Organization (WHO), breast cancer is the most common type of cancer in women worldwide; around 2.15 million women have breast cancer each year, with the highest deaths recorded among women due to cancer. In 2018, an estimated 627,500 women died from breast cancer, accounting for almost 15.69% of all cancer deaths among women worldwide.
Increasing breast cancer screening and minimal radiation exposure procedures are other factors that will drive the market. DBT screening improves breast cancer detection rates and reduces callbacks that raise the patients' prognosis. During a DBT procedure, patients are exposed to higher radiation levels than with 2D mammography. Hence, a decrease in radiation exposure is expected to provide lucrative growth opportunities for players in the market. Regulators should also define the use of DBT in breast cancer screening and its role in diagnosing and staging cancer.
Lack of clinical trials supporting the efficacy of DBT will hamper the growth of the APAC digital breast tomosynthesis (DBT) Equipment market. In addition, lack of devices or skilled labor to perform the procedure coupled with poor healthcare facilities in developing/under-developed countries in the APAC region will challenge the market growth.
This research report on the Asia Pacific Digital Breast Tomosynthesis (DBT) Equipment Market has been segmented and sub-segmented into the following categories
By End User:
In 2020, the China digital breast tomosynthesis equipment market accounted for the largest share in terms of revenue of the APAC digital breast tomosynthesis (DBT) Equipment market. This regional market growth can be linked to advanced healthcare infrastructure, sizeable female population, disposable income, high incidence of breast cancer, and growing demand for digital technology. In 2018, the incidence of breast cancer was 36.18 and 84.94 per 100,000 for China and the United States, respectively. Breast cancer mortality in 2019 was 8.85 and 12.76 per 100,000 for China and the United States, respectively. Therefore, the Chinese market is projected to grow faster in terms of profits during the forecast period.
Over the analysis period, India digital breast tomosynthesis equipment market and Japan digital breast tomosynthesis equipment market will also have a steady growth rate due to the growing number of breast cancer cases in these regions. Breast cancer has been ranked as the number one cancer among Indian women, with a rate of 25.88 per 100,000 women and mortality of 12.73 per 100,000 women.
In 2020, the highest number of breast cancer cases among women in japan was over 90,000. The estimated number of cancer incidences among Japanese women that year was around 430,000 cases.
KEY MARKET PLAYERS
Top Companies leading the Asia Pacific Digital Breast Tomosynthesis (Dbt) Equipment Market Profiled in the Report are Hologic Inc., Siemens Healthineers, Fujifilm Corporation. Other players in the market include GE Healthcare, Internazionale Medico Scientifica S.r.l. and Planmed Oy.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com